Welcome to our dedicated page for CHPM news (Ticker: CHPM), a resource for investors and traders seeking the latest updates and insights on CHPM stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CHPM's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CHPM's position in the market.
CHP Merger Corp. (Nasdaq: CHPM) announced that stockholders approved the Extension Proposal, allowing more time to finalize its business combination with Integrity Implants Inc., also known as Accelus. The deadline for this merger has been extended from November 26, 2021, to May 26, 2022. This decision aims to support the ongoing integration of Accelus's minimally invasive spinal surgery technologies into the market. Details are available in the company's Definitive Proxy Statement filed with the SEC.
CHP Merger Corp. (Nasdaq: CHPM) announced the adjournment of its special meeting of stockholders originally scheduled for November 22, 2021, to vote on extending the deadline for its business combination with Integrity Implants Inc. (d/b/a Accelus) from November 26, 2021, to May 26, 2022. The meeting will reconvene on November 24, 2021, at 9:00 a.m. Eastern Time. Accelus specializes in minimally invasive spinal surgery technologies, aiming to address underserved markets.
CHP Merger Corp. (Nasdaq: CHPM) announced the opportunity for shareholders to reverse redemption requests through a DTC DWAC request ahead of a special meeting on November 24, 2021. This meeting will vote on extending the deadline for completing the initial business combination with Accelus from November 26, 2021, to May 26, 2022. If approved, Accelus will contribute $0.0333 per share monthly to the trust account, totaling up to $0.20 per share for unredeemed stocks. As of September 30, 2021, the trust account held approximately $10.06 per share.
FAQ
What is the market cap of CHPM (CHPM)?
